|Number of pages||3|
|State||Published - Apr 2020|
Bibliographical noteFunding Information:
Dr. Kane has been a consultant for or has received honoraria from Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest, Genentech, H. Lundbeck, Intracellular Therapeutics, Janssen Pharmaceuticals, Johnson and Johnson, Otsuka, Reviva, Roche, Sunovion, and Teva and is a shareholder in LB Pharmaceuticals and Vanguard Research Group. Dr. Petrides has received research support from Amgen, Astra Zeneca, Corcept, Eli Lilly, Proteus, St. Jude Medical, and Sunovion, and he has served on an advisory panel for Corcept. Dr. de Leon received researcher-initiated grants from Eli Lilly (one ended in 2003 and the other, as co-investigator, ended in 2007); from Roche Molecular Systems, Inc. (ended in 2007); and, in a collaboration with Genomas, Inc., from the NIH Small Business Innovation Research program (ended in 2010). J. de Leon has been on the advisory boards of Bristol-Myers Squibb (2003/04) and AstraZeneca (2003). Roche Molecular Systems supported one of his educational presentations, which was published in a peer-reviewed journal (2005). His lectures were supported once by Sandoz (1997), twice by Lundbeck (1999 and 1999), twice by Pfizer (2001 and 2001), three times by Eli Lilly (2003, 2006, and 2006), twice by Janssen (2000 and 2006), once by Bristol-Myers Squibb (2006), and seven times by Roche Molecular Systems, Inc. (once in 2005 and six times in 2006). All other authors declare no conflicts of interest. The original study was supported by an RO1 grant from NIMH to Dr. Petrides (MH-603930). Nevertheless, the retrospective analysis performed here did not receive funds or support from any source.
The original study was supported by an RO1 grant from NIMH to Dr. Petrides ( MH-603930 ).
- Electroconvulsive therapy
- Treatment-resistant schizophrenia
ASJC Scopus subject areas
- Psychiatry and Mental health
- Biological Psychiatry